MiNK Therapeutics
INKT
34 hedge funds and large institutions have $1.06M invested in MiNK Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 5 closing their positions.
32% more capital invested
Capital invested by funds: $800K → $1.06M (+$260K)
0.08% more ownership
Funds ownership: 0.21% → 0.29% (+0.08%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LF
Longbow Finance
Lutry,
Switzerland
|
+$174K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$44K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$36K |
| 4 |
Renaissance Technologies
New York
|
+$35.8K |
| 5 |
Jane Street
New York
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$25.3K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$7.84K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.84K |
| 4 |
BlackRock
New York
|
-$4.22K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$3.67K |
INKT Hedge Fund Activity: Q4 2023 in Review
34 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2023, worth a combined $1.06M — up 32% from $800K a quarter earlier.
Fund positioning in INKT was balanced in Q4 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was Longbow Finance, opening a new position worth an estimated $174K. The largest seller was UBS O'Connor, exiting entirely with an estimated $25.3K sold.
- 34 institutional investors held MiNK Therapeutics (INKT) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.06M of MiNK Therapeutics stock for Q4 2023, up 32% quarter-over-quarter.
- 5 funds opened new MiNK Therapeutics positions in Q4 2023 and 5 closed out, a net change of 0 holders.
- The largest MiNK Therapeutics buyer in Q4 2023 was Longbow Finance, an estimated $174K added.
- The largest MiNK Therapeutics seller in Q4 2023 was UBS O'Connor, an estimated $25.3K sold.
Based on aggregated 13F filings for Q4 2023.